AFS-13-200-E February 22, 2013

Exemption No. 10690A Regulatory Docket No. FAA-2013-0034

Stacey Bechdolt, Esq. Director, Safety & Technical Affairs Regional Airline Association 2025 M Street, NW., Suite 800 Washington, DC 20036

Mr. Douglas Mullen
Assistant General Counsel
Airlines for America 1301 Pennsylvania Avenue, NW, Suite 1100 Washington, DC 20004

Mr. George Paul
Director of Technical Services
National Air Carrier Association 1000 Wilson Boulevard, Suite 1700 Arlington, VA 22209

Dear Ms. Bechdolt:

This letter is to inform you that we have granted your petition to amend Exemption No. 10690. It explains the basis for our decision, describes its effect, and lists the revised
conditions and limitations.

The Basis for Our Decision

By letter dated February 1, 2013, you petitioned the Federal Aviation Adm inistration (FAA) on behalf of Regional Airline Association (RAA) for an amendment to Exemption No. 10690. That exemption from § 121.803(c)(3) and Appendix A of part 121 of Title 14, Code of Federal Regulations (14 CFR) would provide relief from the requirement to include Atropine2

in an Emergency Medical Kit (EMK). The amendment you request would change the name from Silver Airlines to Silver Airways

In your petition, you indicate that there has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition
in the Federal Register because the requested amendment to the exemption would not set a precedent, and any delay in acting on this petition would be detrimental to RAA.

Our Decision

Under the authority contained in 49 U.S.C. §§ 40113 and 44701, which the FAA
Adm inistrator has delegated to me, I hereby grant Regional Airline Association, Airlines for America, and National Air Carrier Associa tion an exemption from 14 CFR § 121.803(c)(3) and Appendix A of part 121, to the extent necessary to relieve them from the requirement to carry two single dose ampules of Atropine 5cc injectable, in required on-board EMKs when, due to the nationwide shortage discussed herein, they are unable to procure these items for the kits, subject to the following revised conditions and limitations.

Conditions and Limitations

1. This exem ption applies to the part 119 certificate holders authorized to conduct part 121 passenger carrying operations listed below.

Air Transport International ExpressJet Republic Airlines
Air Wisconsin Airlines Corp. GoJet Ryan International Airlines

Alaska Airlines Great Lakes Aviation Seaborne Airlines Allegiant Air Hawaiian Airlines, Inc. Shuttle America
American Airlines Horizon Air Silver Airways American Eagle Island Air SkyWest Airlines, Inc. Atlas Air, Inc. JetBlue Airways Corp. Southwest Airlines, Inc. Cape Air Miami Air International Sun Country Airlines Chatauqua Airlines National Airlines Trans States Airlines
CommutAir National Air Cargo United Airlines, Inc. Compass Airlines Omni Air International US Airways, Inc. Delta Air Lines, Inc. Piedmont Airlines USA Jet Airlines
Era Aviation Pinnacle Airlines, Inc. World Airways Everts Air Cargo PSA Airlines

2. A copy of this exemption must be carried on board each aircraft operating with emergency medical kits that do not include Atropine as required by Appendix A of part 121.3

3. The pilot in command must inform crewmembers that any emergency medical kits on board the aircraft may not contain Atropine as part of the pre-flight briefing.

4. This exemption may be used for flights conducted outside of the United States.

The Effect of Our Decision

The term ination date of Exemption No. 10690 remains January 31, 2014, unless sooner superseded or rescinded.

Sincerely,

/s/
Michael J. Zenkovich Acting Deputy Director, Flight Standards
Service